ADMP stock is a member of the Drug Manufacturers – Specialty & Generic industry. According to Zacks Investment Research, the stock has a consensus rating of Hold. Two analysts have rated the stock as a Buy or a Strong Buy, while two analysts rate it a Sell.
The current EPS for Adamis Pharmaceuticals is -$0.27, but analysts expect it to grow to $0.15 by 2022. The lowest EPS forecast is -$0.14, while the highest is -$0.04. For the next three years, ADMP’s EPS is expected to increase by $0.03 per share, and analysts are projecting that EPS will grow to $1.00 by 2024.